Argos Therapeutics (ARGS) Reports Q3 Loss of $0.10/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. SPY

Go back to Argos Therapeutics (ARGS) Reports Q3 Loss of $0.10/Share

Argos Reports Third Quarter 2017 Financial Results and Operational Highlights

November 9, 2017 4:46 PM EST

DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ: ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported financial results and operational highlights for the third quarter of 2017.

We are pleased with the progress we have made since the second quarter, both with regard to our financial position as well as in our two clinical programs, Jeff Abbey, CEO of Argos Therapeutics, noted. First, from a financial perspective, we are pleased to have raised... More